Page results
-
As an organisation, UCLH needs to minimise the environmental impact of our buildings and the energy they use and maximise our use of any technology available to support these changes. This page outlines our progress to date.
-
A UCLH patient with a rare hormonal condition is the first in the world to receive a new investigational drug in a first-in-human trial.
-
We provide routine histopathological diagnoses using both standard techniques and advanced diagnostics including immunocytochemistry, fluoresent in-situ hybridisation (FISH), and polymerase chain…
-
This page offers ways you can help us to prevent infection and make your babies safer.
-
Overall, most women (over 90%) spontaneously give birth to their baby after 37 weeks of pregnancy, called term delivery. Approximately 10%, or 1 in 10 women spontaneously give birth to their baby…
-
This page has been written to provide information to those women who choose to decline a blood transfusion or blood products. It is important for you to know that your decision is respected and that…
File results
-
FOI/2023/0516 - Maternity management system
-
FOI/2023/0522 - Urology cancer pathway
-
FOI/2023/0523 - Treatment on Nivolumab
-
FOI/2023/0537 - Agency usage for the Occupational Therapy
-
FOI/2023/0542 - Pulmonary rehabilitation (PR)
-
FOI/2023/0569 - Treatment for Ruxolitinib
-
FOI/2023/0565 - Rare diseases - diagnosis/ treatment for Fabry/ Gaucher/ Pompe
-
FOI/2023/0566 - Structure chart for IM &T, Business Intelligence, Informatics
-
FOI/2023/0563 - Treatment for Haemophilia B and Von Willebrand disease
-
FOI/2023/0578 - Spinal Muscular Atrophy (SMA) patients